ArticleAdvanced biomedical research2026
Designing a Vaccine for the Monkeypox Virus Using Immunoinformatics and Structural Tools.
Article in Advanced biomedical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Monkeypox virus (MPXV) causes mpox, and vaccination is the most effective method of prevention. This project utilized immunoinformatics tools to design a multiepitope subunit vaccine against Mpox. Materials and Methods: Seven MPXV antigens (B18R, B21R, D2L, E8L, N3R, I1L, and N2R) were selected based on a literature review, and their sequences were retrieved with the signal peptides and transmembrane domains omitted. B cell, T cell, MHC-I, and MHC-II epitopes were evaluated, followed by tertiary structure and homology modeling. The physicochemical properties of the construct were assessed, molecular docking was conducted with murine Toll-like receptors, and codon optimization was performed. Results: Three sequences were excluded: B18R lacked appropriate epitopes, N2R was predicted to be an allergen by AllergenFP software, and I1L lacked antigenicity. The final vaccine construct incorporated segments from four genes, along with two adjuvants and two T-helper molecules linked by short sequences. The designed protein had a pI of 7.96, a molecular weight of approximately 16 kDa, an energy value of -723.06, a codon frequency distribution of 100, and a codon adaptation index of 0.88. The construct was subsequently cloned and inserted into a pET-28a(+) vector to generate a recombinant plasmid. Conclusions: Using immunoinformatics techniques, a novel multiepitope vaccine construct for MPXV was successfully designed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.